Journal Article

Valganciclovir, a More Potent Oral Therapy for CMV Retinitis in AIDS, Approved by FDA

Donald Kaye

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 32, issue 9, pages ii-ii
Published in print May 2001 | ISSN: 1058-4838
Published online May 2001 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/cid/32.9.ii
Valganciclovir, a More Potent Oral Therapy for CMV Retinitis in AIDS, Approved by FDA

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Journal Article.  517 words. 

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.